539 related articles for article (PubMed ID: 17699324)
41. [A case of hyperaldosteronism in childhood].
Cserháti E; Körner A
Orv Hetil; 1980 Jun; 121(24):1453-5. PubMed ID: 6108546
[No Abstract] [Full Text] [Related]
42. Association of kidney function with residual hypertension after treatment of aldosterone-producing adenoma.
; Wu VC; Chueh SC; Chang HW; Lin LY; Liu KL; Lin YH; Ho YL; Lin WC; Wang SM; Huang KH; Hung KY; Kao TW; Lin SL; Yen RF; Chen YM; Hsieh BS; Wu KD
Am J Kidney Dis; 2009 Oct; 54(4):665-73. PubMed ID: 19628318
[TBL] [Abstract][Full Text] [Related]
43. Resistant hypertension and aldosterone: an update.
Clark D; Ahmed MI; Calhoun DA
Can J Cardiol; 2012 May; 28(3):318-25. PubMed ID: 22521297
[TBL] [Abstract][Full Text] [Related]
44. Renin and hypertension.
Verniory A; Staroukine M; Delwiche F
Brux Med; 1973 Nov; Spec No(0):63-86. PubMed ID: 4371909
[No Abstract] [Full Text] [Related]
45. Aldosterone and Cardiovascular Disease. Foreword.
Rahimtoola SH
Curr Probl Cardiol; 2009 Feb; 34(2):49. PubMed ID: 19135615
[No Abstract] [Full Text] [Related]
46. [Mineralocorticoid hypertension. A new form of secondary hypertension?].
Román O
Rev Med Chil; 1999 May; 127(5):511-3. PubMed ID: 10451619
[TBL] [Abstract][Full Text] [Related]
47. [Diagnosis and therapy of arterial hypertension. Significance of the renin-angiotensin-aldosterone system in differential diagnosis and therapy].
Nast HP; Philipp T
Fortschr Med; 1974 Apr; 92(11):447-51. PubMed ID: 4362672
[No Abstract] [Full Text] [Related]
48. Resistant hypertension and aldosteronism.
Pimenta E; Calhoun DA
Curr Hypertens Rep; 2007 Nov; 9(5):353-9. PubMed ID: 18177580
[TBL] [Abstract][Full Text] [Related]
49. More fuel to the debate on the "epidemics of primary aldosteronism".
Rossi GP; Pessina AC; Mantero F;
Hypertension; 2008 Jan; 51(1):e1-2; author reply e3. PubMed ID: 18039978
[No Abstract] [Full Text] [Related]
50. QT interval in patients with primary aldosteronism and low-renin essential hypertension.
Maule S; Mulatero P; Milan A; Leotta G; Caserta M; Bertello C; Rabbia F; Veglio F
J Hypertens; 2006 Dec; 24(12):2459-64. PubMed ID: 17082730
[TBL] [Abstract][Full Text] [Related]
51. Spironolactone for the treatment of isolated systolic hypertension.
Yarows SA
Am J Hypertens; 2004 Mar; 17(3):284. PubMed ID: 15001208
[No Abstract] [Full Text] [Related]
52. Blood pressure and serum potassium levels in hypertensive patients receiving or not receiving antihypertensive treatment.
Pikilidou MI; Lasaridis AN; Sarafidis PA; Tziolas IM; Zebekakis PE; Dombros NV; Giannoulis E
Clin Exp Hypertens; 2007 Nov; 29(8):563-73. PubMed ID: 18058481
[TBL] [Abstract][Full Text] [Related]
53. [Diagnosis of primary hyperaldosteronism].
Diederich S; Bidlingmaier M; Quinkler M; Reincke M
Med Klin (Munich); 2007 Jan; 102(1):16-21. PubMed ID: 17221347
[TBL] [Abstract][Full Text] [Related]
54. [New data on hormone-dependent hypertension and their significance for the practice].
Horký K; Petrásek J; Marek J
Cas Lek Cesk; 1973 Jan; 112(1):3-11. PubMed ID: 4345613
[TBL] [Abstract][Full Text] [Related]
55. Long-term effect of efonidipine therapy on plasma aldosterone and left ventricular mass index in patients with essential hypertension.
Tsutamoto T; Tanaka T; Nishiyama K; Yamaji M; Kawahara C; Fujii M; Yamamoto T; Horie M
Hypertens Res; 2009 Aug; 32(8):670-4. PubMed ID: 19498438
[TBL] [Abstract][Full Text] [Related]
56. Immunoreactive endogenous ouabain in primary aldosteronism and essential hypertension: relationship with plasma renin, aldosterone and blood pressure levels.
Rossi G; Manunta P; Hamlyn JM; Pavan E; De Toni R; Semplicini A; Pessina AC
J Hypertens; 1995 Oct; 13(10):1181-91. PubMed ID: 8586810
[TBL] [Abstract][Full Text] [Related]
57. Aldosterone revisited.
Kleta R; O'Brien K
N Engl J Med; 2004 Nov; 351(20):2131-3; author reply 2131-3. PubMed ID: 15543661
[No Abstract] [Full Text] [Related]
58. Mineralocorticoid receptor-associated hypertension and its organ damage: clinical relevance for resistant hypertension.
Shibata H; Itoh H
Am J Hypertens; 2012 May; 25(5):514-23. PubMed ID: 22258336
[TBL] [Abstract][Full Text] [Related]
59. Resistant hypertension: who and how to evaluate.
Acelajado MC; Calhoun DA
Curr Opin Cardiol; 2009 Jul; 24(4):340-4. PubMed ID: 19395953
[TBL] [Abstract][Full Text] [Related]
60. Effect of short-term losartan treatment in patients with primary aldosteronism and essential hypertension.
Zacharieva S; Atanassova I; Natchev E; Orbetzova M; Tzingilev D
Methods Find Exp Clin Pharmacol; 2001 Apr; 23(3):153-6. PubMed ID: 11523316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
